Belantamab Mafodotin

BLENREP®

Verified

Overview

Belantamab Mafodotin (BLENREP®) is an antibody-drug conjugate (ADC) with anti-BCMA antibody that binds to BCMA on tumor cell surfaces causing cell cycle arrest and inducing antibody-dependent cellular cytotoxicity (ADCC). Belantamab Mafodotin is currently FDA approved for use in multiple myeloma patients who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. It is investigational in all other uses. Patients can click here to locate providers of Belantamab Mafodotin (BLENREP®).

On November 22, 2022, GSK announced that it has initiated the process for withdrawal of the US marketing authorization for Blenrep following the request of the US Food and Drug Administration (FDA). This request was based on the previously announced outcome of the DREAMM-3 phase III confirmatory trial, which did not meet the requirements of the US FDA Accelerated Approval regulations. Learn More

SparkCures ID 130
Developed By GlaxoSmithKline
Brand Name Blenrep®
Generic Name Belantamab Mafodotin
Additional Names GSK2857916
Treatment Classifications
Treatment Targets

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Verified
A Phase III Study of Belantamab Mafodotin plus Pomalidomide and Dexamethasone vs Pomalidomide, Bortezomib and Dexamethasone in Participants with Relapsed / R...
DREAMM8
View Trial
Verified
Platform Study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with Relapsed/Refractory Mu...
DREAMM5
View Trial
Verified
Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma
View Trial
Verified
A Study of Belantamab Mafodotin in Combination With and Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or ...
View Trial
Verified
A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
BELANTAMAB MAFODOTIN
View Trial
Verified
A Study of Belantamab Mafodotin (GSK2857916) in Multiple Myeloma Participants With Normal and Varying Degrees of Impaired Renal Function
DREAMM12
View Trial
Verified
A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function
DREAMM13
View Trial
Verified
A Phase 1 Study of Belantamab Mafodotin Plus Standard of Care in Newly Diagnosed Multiple Myeloma
DREAMM9
View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

Expanded Access Request Program for Belantamab Mafodotin (GSK2857916) in Multiple Myeloma
View Trial
Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or R...
DREAMM 14
View Trial
Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Recep...
EMBRACE
View Trial
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
View Trial
Phase II Study of Belantamab Mafodotin in Combination With Carfilzomib, Pomalidomide, and Dexamethasone (KP...
BELANTAMAB MAFODOTIN
View Trial
A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma
View Trial
A Phase II Study of ISABELA: Isatuximab, Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Relapsed ...
ISABELA
View Trial
Myeloma-Developing Regimens Using Genomics
MYDRUG
View Trial
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
BELANTAMAB MAFODOTIN
View Trial
Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
BELANTAMAB MAFODOTIN
View Trial
Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
View Trial
A Phase 1/2 Open-label, Multicentre, Dose Escalation and Expansion Study to Investigate the Safety, Tolerab...
DREAMM-20
View Trial
Untreated / Newly Diagnosed Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.

Verified
A Phase 1 Study of Belantamab Mafodotin Plus Standard of Care in Newly Diagnosed Multiple Myeloma
DREAMM9
View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
BELANTAMAB MAFODOTIN
View Trial
Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Verified
A Phase III Study of Belantamab Mafodotin plus Pomalidomide and Dexamethasone vs Pomalidomide, Bortezomib and Dexamethasone in Participants with Relapsed / R...
DREAMM8
View Trial
Verified
Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma
View Trial
Verified
A Study of Belantamab Mafodotin (GSK2857916) in Multiple Myeloma Participants With Normal and Varying Degrees of Impaired Renal Function
DREAMM12
View Trial
Verified
A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function
DREAMM13
View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

Phase II Study of Belantamab Mafodotin in Combination With Carfilzomib, Pomalidomide, and Dexamethasone (KP...
BELANTAMAB MAFODOTIN
View Trial
A Phase II Study of ISABELA: Isatuximab, Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Relapsed ...
ISABELA
View Trial
Myeloma-Developing Regimens Using Genomics
MYDRUG
View Trial
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
BELANTAMAB MAFODOTIN
View Trial
A Phase 1/2 Open-label, Multicentre, Dose Escalation and Expansion Study to Investigate the Safety, Tolerab...
DREAMM-20
View Trial
Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Verified
A Phase III Study of Belantamab Mafodotin plus Pomalidomide and Dexamethasone vs Pomalidomide, Bortezomib and Dexamethasone in Participants with Relapsed / R...
DREAMM8
View Trial
Verified
Platform Study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with Relapsed/Refractory Mu...
DREAMM5
View Trial
Verified
Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma
View Trial
Verified
A Study of Belantamab Mafodotin in Combination With and Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or ...
View Trial
Verified
A Study of Belantamab Mafodotin (GSK2857916) in Multiple Myeloma Participants With Normal and Varying Degrees of Impaired Renal Function
DREAMM12
View Trial
Verified
A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function
DREAMM13
View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

Expanded Access Request Program for Belantamab Mafodotin (GSK2857916) in Multiple Myeloma
View Trial
Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or R...
DREAMM 14
View Trial
Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Recep...
EMBRACE
View Trial
Phase II Study of Belantamab Mafodotin in Combination With Carfilzomib, Pomalidomide, and Dexamethasone (KP...
BELANTAMAB MAFODOTIN
View Trial
A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma
View Trial
A Phase II Study of ISABELA: Isatuximab, Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Relapsed ...
ISABELA
View Trial
Myeloma-Developing Regimens Using Genomics
MYDRUG
View Trial
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
BELANTAMAB MAFODOTIN
View Trial
Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
BELANTAMAB MAFODOTIN
View Trial
Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
View Trial
A Phase 1/2 Open-label, Multicentre, Dose Escalation and Expansion Study to Investigate the Safety, Tolerab...
DREAMM-20
View Trial
Smoldering Myeloma

The following is a listing of clinical trials for patients with Smoldering Myeloma.

Verified
A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
BELANTAMAB MAFODOTIN
View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

Monoclonal Gammopathy of Undetermined Significance (MGUS)

Published Results

Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs).

June 01, 2020

  • Single-agent belantamab mafodotin (B-cell maturation antigen targeting immunoconjugate) showed clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed/refractory multiple myeloma (DREAMM-2, NCT03525678, Lancet Oncol.2020).
  • ORR was 31% in the 2.5 mg/kg (19% with ≥very good partial responses [VGPR]) and 35% (24% with ≥VGPR) in the 3.4 mg/kg groups.
  • Duration of response (DoR) was not reached (NR) in the 2.5 mg/kg and 6.2 months in the 3.4 mg/kg groups;
  • 1-year overall survival (OS) estimate was 53%.
Read More

Resources

GSK provides an update on Blenrep (belantamab mafodotin-blmf) US marketing authorization

November 22, 2022

Read More
FDA approves GSK’s BLENREP (belantamab mafodotin-blmf) for the treatment of patients with relapse...

August 06, 2020

Read More
Belantamab Mafodotin Induces Deep and Durable Responses in R/R Myeloma

September 29, 2022

Read More
Belantamab Mafodotin Elicits Deep, Durable Responses in Heavily Pretreated Relapsed/Refractory My...

December 06, 2020

Read More
FDA Panel Supports Belantamab Mafodotin for Relapsed/Refractory Myeloma

July 14, 2020

Read More
GlaxoSmithKline : GSK announces FDA Advisory Committee meeting to review belantamab mafodotin for...

June 19, 2020

Read More
US Food and Drug Administration (FDA) grants priority review of belantamab mafodotin for patients...

January 21, 2020

Read More
SpringWorks Therapeutics Announces Global Clinical Collaboration with GlaxoSmithKline to Evaluate...

June 27, 2019

Read More
GSK announces further positive data from DREAMM-1 study of anti-BCMA antibody-drug conjugate in p...

March 21, 2019

Read More
GSK2857916 Demonstrates 60% Response Rate in Heavily Pre-treated Relapsed/Refractory Multiple Mye...

December 12, 2017

Read More
BLENREP® Certified Participant Locator

Patients can locate providers of Belantamab Mafodotin (BLENREP®) based on location/zip code.

Learn More
GSK Compassionate Use (Expanded Access) Request Portal

GSK recognises that there may be circumstances when it is appropriate for Healthcare Professionals to give their patients Investigational medicines to treat life threatening or seriously debilitating diseases/conditions where no satisfactory alternatives exist.

Learn More
SparkCures Verified

SparkCures is working closely with GlaxoSmithKline to provide the most up-to-date information on this treatment. Use the button above to add this treatment to your list of favorites.

Learn more about how we work with industry partners